Literature DB >> 3140911

Differential expression of adenosine deaminase isozymes in acute leukemia.

H Ratech1, F Martiniuk, W Z Borer, H Rappaport.   

Abstract

Total adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) activities were measured in cell samples from 13 cases of de novo acute leukemia and from three cases of chronic myeloid leukemia in blast crisis (CMLBC). These cases could be separated into lymphoid and nonlymphoid types on the basis of enzyme activity, with two misclassifications. However, PNP activity added little or no discriminatory information. Analysis for expression of the various molecular weight (mol wt) ADA isozymes, ADA1 (40 Kd) and ADA2 (110 Kd), revealed that ADA2 was expressed exclusively in nonlymphoid cells whereas ADA1 was found in both lymphoid and nonlymphoid cell types. Identification of ADA2 divided these leukemia cases into lymphoid and nonlymphoid types with no misclassifications (P = .0002; Fisher's exact test). Acute nonlymphoblastic leukemia (ANLL) with a monocytic component tended to have a greater percentage of ADA2 than ANLL without a monocytic component. These studies suggest that ADA2 may be a novel biochemical marker for an immature nonlymphoid cell.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3140911

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Macrophages are a source of extracellular adenosine deaminase-2 during inflammatory responses.

Authors:  B A Conlon; W R Law
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

2.  Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern.

Authors:  Reza Saghiri; Niloufar Ghashghai; Shafieh Movaseghi; Pegah Poursharifi; Shohreh Jalilfar; Manijeh Ahmadi Bidhendi; Leila Ghazizadeh; Mina Ebrahimi-Rad
Journal:  Rheumatol Int       Date:  2011-02-25       Impact factor: 2.631

Review 3.  Mechanisms of vascular inflammation in deficiency of adenosine deaminase 2 (DADA2).

Authors:  Pui Y Lee; Ivona Aksentijevich; Qing Zhou
Journal:  Semin Immunopathol       Date:  2022-02-17       Impact factor: 9.623

4.  Adenosine deaminase isoenzyme levels in patients with human T-cell lymphotropic virus type 1 and human immunodeficiency virus type 1 infections.

Authors:  I Tsuboi; K Sagawa; S Shichijo; M M Yokoyama; D W Ou; M D Wiederhold
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

5.  Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.

Authors:  Pui Y Lee; Grant S Schulert; Scott W Canna; Yuelong Huang; Jacob Sundel; Ying Li; Kacie J Hoyt; Rachel B Blaustein; Alexandra Wactor; Thuy Do; Olha Halyabar; Margaret H Chang; Fatma Dedeoglu; Siobhan M Case; Esra Meidan; Mindy S Lo; Robert P Sundel; Edward T Richardson; Jane W Newburger; Michael S Hershfield; Mary Beth Son; Lauren A Henderson; Peter A Nigrovic
Journal:  Ann Rheum Dis       Date:  2019-11-09       Impact factor: 19.103

Review 6.  Vasculopathy, Immunodeficiency, and Bone Marrow Failure: The Intriguing Syndrome Caused by Deficiency of Adenosine Deaminase 2.

Authors:  Pui Y Lee
Journal:  Front Pediatr       Date:  2018-10-18       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.